| Name | Title | Contact Details |
|---|
Exonics Therapeutics was launched in February 2017 to advance the research of our scientific founder, Dr. Eric Olson and his laboratory at the University of Texas Southwestern Medical Center (UTSW) to develop treatments for patients with neuromuscular diseases. Dr. Olson is one of the world’s leading experts in the study of muscle cells and the application of gene editing to treat these types of diseases. In particular, Dr. Olson’s laboratory has used adeno-associated virus (AAV) to deliver a CRISPR/Cas9 technology that can identify and repair exon mutations to restore the production of dystrophin, a protein that helps stabilize and protect muscle fibers. Dystrophin is the protein missing in boys with Duchenne. The loss of dystrophin causes Duchenne.
Vium is the first company to create a living informatics platform for preclinical in vivo drug research.
PAR Management is a Newton, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Rockland Immunochemicals is a Gilbertsville, PA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Parental Therapy Associates is a Altamonte Springs, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.